Investor Presentation Q1 2018

Investor Presentation First three months of 2018 The GLP-1 segment accounts for 15% of total diabetes care market value in North America Slide 67 North America GLP-1 market GLP-1 value in bDKK VictozaⓇ dulaglutide OzempicⓇ other exenatide Share of total diabetes care . 60 market 14% Key observations for Victoza® in the US market VictozaⓇ value market share within the GLP-1 segment is 54%¹ 50 12% CAGR value¹: 38.0% Around 80% of Commercial and around 90% of Medicare Part D GLP-1 market volume is covered without restrictions² 10% 40 8% 30 . Around 93% of new patients who start on VictozaⓇ transition from outside of GLP-1 segment³ 6% 20 4% • 10 2% Around 71% of prescriptions are for the higher dose 1.8 mg4 0 0% Feb Feb 2013 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) changing diabetes Source: IQVIA NSP monthly, MAT Feb 2018 FingerTip Formulary bridge/ February 2018 Nomenclature and Xponent PlanTrak using week-ending 2 March 2018; only considers bridged volume; excludes cash and mail order data; 1. 2. 3. IQVIA SOB, week ending 23 March 2018 4. IQVIA weekly NPA, week ending 30 March 2018 novo nordisk

View entire presentation